SWOG Statistical Center, Seattle, WA, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Leuk Lymphoma. 2021 Aug;62(8):1967-1972. doi: 10.1080/10428194.2021.1885663. Epub 2021 Mar 10.
Among acute myeloid leukemia (AML) patients treated with 7 + 3 induction, we evaluate the association between complete morphologic remission (CR) and long-term overall survival (OS) over four decades. We analyzed 1247 patients age 65 randomized to 7 + 3 arms from five SWOG studies. OS has improved over the four decades. Hazards for death in the two most recent studies fell after year 2. In multivariable models, decade of therapy was the most important variable with respect to long-term survival and CR by day 100 the second most important variable. Protocol/decade, which captures many factors not included in our multivariable model, was the most important predictor of being alive at year 2 or 3. The next most important factor was achievement of first CR by day 100.
在接受 7+3 诱导治疗的急性髓系白血病 (AML) 患者中,我们评估了长达四个十年的完全形态缓解 (CR) 与长期总生存 (OS) 之间的关联。我们分析了来自五个 SWOG 研究的 1247 名年龄在 65 岁的随机分配到 7+3 组的患者。OS 在过去的四十年中得到了改善。在第 2 年后,最近两项研究中死亡的风险降低。在多变量模型中,治疗的十年是与长期生存和第 100 天 CR 相关的最重要变量,而第 100 天的 CR 是第二重要变量。方案/十年是多变量模型中未包含的许多因素的最重要预测因子,是在第 2 年或第 3 年存活的最重要预测因子。下一个最重要的因素是在第 100 天达到首次 CR。